Catalent, Inc. (NYSE:CTLT) Shares Bought by Toronto Dominion Bank

Toronto Dominion Bank increased its stake in Catalent, Inc. (NYSE:CTLT) by 270.7% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 388,747 shares of the company’s stock after acquiring an additional 283,870 shares during the period. Toronto Dominion Bank owned approximately 0.21% of Catalent worth $21,859,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of CTLT. Lindbrook Capital LLC grew its position in Catalent by 79.4% during the first quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock valued at $27,000 after acquiring an additional 208 shares during the period. Thurston Springer Miller Herd & Titak Inc. acquired a new position in shares of Catalent in the 2nd quarter valued at about $42,000. Mather Group LLC. purchased a new stake in shares of Catalent during the 1st quarter worth about $52,000. Longfellow Investment Management Co. LLC increased its position in Catalent by 45.7% during the 2nd quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock worth $55,000 after purchasing an additional 305 shares in the last quarter. Finally, GAMMA Investing LLC raised its holdings in Catalent by 25.9% in the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock valued at $58,000 after buying an additional 212 shares during the period.

Catalent Stock Up 0.7 %

Shares of Catalent stock opened at $60.29 on Friday. The company has a debt-to-equity ratio of 1.35, a current ratio of 2.52 and a quick ratio of 1.96. Catalent, Inc. has a 1-year low of $31.80 and a 1-year high of $61.20. The business has a 50-day moving average of $59.64 and a 200-day moving average of $57.31. The company has a market capitalization of $10.91 billion, a PE ratio of -9.88, a P/E/G ratio of 2.32 and a beta of 1.15.

Catalent (NYSE:CTLT) last posted its quarterly earnings data on Thursday, August 29th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.13. The company had revenue of $1.30 billion for the quarter, compared to the consensus estimate of $1.23 billion. Catalent had a negative return on equity of 0.56% and a negative net margin of 22.72%. As a group, equities analysts forecast that Catalent, Inc. will post 0.85 EPS for the current fiscal year.

Insider Activity at Catalent

In other Catalent news, SVP Scott Gunther sold 666 shares of the firm’s stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $59.55, for a total transaction of $39,660.30. Following the completion of the transaction, the senior vice president now directly owns 39,635 shares of the company’s stock, valued at approximately $2,360,264.25. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, CFO Matti Masanovich sold 2,993 shares of the business’s stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $56.74, for a total value of $169,822.82. Following the completion of the sale, the chief financial officer now directly owns 33,871 shares in the company, valued at approximately $1,921,840.54. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Scott Gunther sold 666 shares of the firm’s stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $59.55, for a total value of $39,660.30. Following the transaction, the senior vice president now owns 39,635 shares in the company, valued at $2,360,264.25. The disclosure for this sale can be found here. Insiders have sold 13,409 shares of company stock valued at $782,923 over the last ninety days. Corporate insiders own 0.31% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Royal Bank of Canada reiterated a “sector perform” rating and set a $63.50 price objective on shares of Catalent in a research note on Thursday, July 11th. Baird R W cut shares of Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday. Barclays raised their price objective on Catalent from $47.00 to $63.00 and gave the company an “equal weight” rating in a research report on Friday, June 28th. Robert W. Baird reaffirmed a “neutral” rating and issued a $63.50 target price on shares of Catalent in a research report on Tuesday. Finally, StockNews.com initiated coverage on Catalent in a report on Thursday. They set a “sell” rating on the stock. One investment analyst has rated the stock with a sell rating and eight have given a hold rating to the company’s stock. Based on data from MarketBeat.com, Catalent presently has an average rating of “Hold” and a consensus price target of $59.83.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.